Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CVAC

CureVac N.V

Dec 13 • 04:00PM ET

3.16

Dollar change -0.04
Percentage change -1.25	%

Healthcare • Biotechnology • Germany • NASD

Peers: MRNA BNTX PFE NVAX INO ARCT VIR VXRT ALNY

| Held by: IBB IDNA ONEQ SPDW BBC BIB WDNA

Scroll to Statements

Index	-	P/E	5.82	EPS (ttm)	0.54	Insider Own	58.26%	Shs Outstand	224.34M	Perf Week	1.94%
Market Cap	708.81M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.00%	Shs Float	93.63M	Perf Month	14.91%
Income	123.50M	PEG	-	EPS next Q	-0.22	Inst Own	5.18%	Short Float	4.50%	Perf Quarter	-3.36%
Sales	595.81M	P/S	1.19	EPS this Y	168.03%	Inst Trans	-6.56%	Short Ratio	8.48	Perf Half Y	-13.90%
Book/sh	3.61	P/B	0.88	EPS next Y	-164.63%	ROA	13.38%	Short Interest	4.21M	Perf Year	-40.26%
Cash/sh	2.74	P/C	1.15	EPS next 5Y	-10.76%	ROE	17.08%	52W Range	2.21 - 6.30	Perf YTD	-24.94%
Dividend Est.	-	P/FCF	6.26	EPS past 5Y	-23.15%	ROI	14.57%	52W High	-49.84%	Beta	2.58
Dividend TTM	-	Quick Ratio	6.19	Sales past 5Y	54.58%	Gross Margin	67.78%	52W Low	42.66%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	6.20	EPS Y/Y TTM	135.95%	Oper. Margin	30.20%	RSI (14)	59.83	Volatility	6.15% 6.28%
Employees	1172	Debt/Eq	0.06	Sales Y/Y TTM	1202.27%	Profit Margin	20.73%	Recom	2.17	Target Price	6.80
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	797.21%	Payout	-	Rel Volume	0.61	Prev Close	3.20
Sales Surprise	14253.43%	EPS Surprise	3.85%	Sales Q/Q	2925.93%	Earnings	Nov 12 BMO	Avg Volume	496.35K	Price	3.16
SMA20	9.75%	SMA50	11.09%	SMA200	-0.07%	Trades		Volume	300,779	Change	-1.25%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-24	Downgrade	Leerink Partners	Outperform → Market Perform	$12 → $4
Jun-08-23	Initiated	SVB Securities	Outperform	$13
Jan-19-23	Upgrade	UBS	Neutral → Buy	$8 → $18
Jan-09-23	Upgrade	Jefferies	Hold → Buy	$9 → $21
Jan-21-22	Downgrade	BofA Securities	Neutral → Underperform	$55 → $20
Jan-18-22	Initiated	JMP Securities	Mkt Outperform	$52
Oct-22-21	Initiated	Deutsche Bank	Hold	$35
Jun-17-21	Downgrade	BofA Securities	Buy → Neutral	$50
Apr-26-21	Resumed	Credit Suisse	Underperform
Apr-26-21	Initiated	Guggenheim	Neutral
Dec-10-20	Downgrade	Credit Suisse	Neutral → Underperform	$50 → $47
Sep-08-20	Initiated	Jefferies	Hold	$58
Sep-08-20	Initiated	Credit Suisse	Neutral	$68
Sep-08-20	Initiated	BofA Securities	Buy	$70

Show Previous Ratings

Nov-20-24 11:18AM	Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? (Zacks)
Nov-19-24 06:31PM	Is CureVac N.V. (CVAC) the Best German Stock to Buy Now? (Insider Monkey)
Nov-15-24 02:08AM	Where are they now? 4 biotechs that soared then crashed during the pandemic (Pharma Voice)
Nov-13-24 02:13AM	CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ... (GuruFocus.com)
Nov-12-24 07:20AM	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update (ACCESSWIRE)
07:30AM	Loading…
Nov-07-24 07:30AM	CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 (ACCESSWIRE)
Nov-04-24 07:20AM	CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer (ACCESSWIRE)
07:15AM	CureVac to Present at the 12th International mRNA Health Conference (ACCESSWIRE)
Oct-30-24 07:34AM	GSK Cuts Vaccine Sales Outlook Amid U.S. Weakness (The Wall Street Journal)
Oct-28-24 08:10AM	CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (ACCESSWIRE)
Oct-22-24 06:24PM	Analyst Report: CureVac N.V. (Morningstar Research)
Oct-08-24 05:50AM	Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents (Reuters)
Sep-13-24 08:15AM	CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress (ACCESSWIRE) +11.33%
Sep-12-24 07:15AM	CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program (ACCESSWIRE)
Sep-09-24 07:15AM	CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress (ACCESSWIRE) +6.57%
07:07PM	Loading…
Aug-16-24 07:07PM	Analyst Report: CureVac N.V. (Morningstar Research)
Aug-15-24 07:30AM	CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update (ACCESSWIRE)
07:20AM	CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma (ACCESSWIRE)
07:15AM	CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board (ACCESSWIRE)
Aug-08-24 10:00AM	CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-15-24 12:00PM	CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +10.43%
Jul-12-24 10:53AM	CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
Jul-11-24 07:15AM	CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech (ACCESSWIRE) +5.14%
07:00AM	Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer (Business Wire)
Jul-04-24 09:58PM	Analyst Report: CureVac N.V. (Morningstar Research)
06:33AM	CureVac announces restructuring to focus on mRNA projects (Pharmaceutical Technology)
Jul-03-24 12:49PM	GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines (Investopedia) -6.59%
12:41PM	Southwest Airlines Adopts a Poison Pill Plan: 7 Things to Know (InvestorPlace)
11:49AM	CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts (InvestorPlace)
11:12AM	GOEV Stock: Canoo Receives Fleet Order From Go2 Delivery (InvestorPlace)
10:51AM	Loading…
10:51AM	DM Stock Alert: Nano Dimension Is Scooping Up Desktop Metal for $183 Million (InvestorPlace)
10:18AM	GSK Will Pay Up to $1.5 Billion for CureVacs mRNA Vaccines (Barrons.com)
10:09AM	CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK (InvestorPlace)
08:19AM	Stocks to Watch Wednesday: Paramount, Tesla, Constellation Brands (The Wall Street Journal)
07:43AM	CureVac cuts jobs, licenses out vaccines to GSK (BioPharma Dive)
07:21AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
06:23AM	GSK to Buy CureVacs Covid-19, Flu Vaccine Rights for Up to $1.56 Billion (The Wall Street Journal)
06:12AM	GSK and CureVac restructure mRNA vaccine development deal (Pharmaceutical Technology)
04:43AM	GSK pays CureVac $430M for mRNA vaccines against flu and COVID as partner lays off 30% (FierceBiotech.com)
02:40AM	GSK and CureVac to Restructure Collaboration into New Licensing Agreement (ACCESSWIRE)
02:40AM	CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities (ACCESSWIRE)
02:25AM	GSK buys COVID, influenza vaccines from retrenching CureVac (Reuters)
Jun-24-24 04:20PM	CureVac Announces Voting Results of General Meeting (ACCESSWIRE) +6.44%
Jun-18-24 06:59PM	Analyst Report: CureVac N.V. (Morningstar Research) -6.61%
Jun-03-24 06:48PM	Analyst Report: CureVac N.V. (Morningstar Research) +11.57% -6.91%
May-28-24 07:20AM	CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK (ACCESSWIRE)
May-23-24 07:58PM	Analyst Report: CureVac N.V. (Morningstar Research) -7.05%
12:45PM	Heard on the Street: Moderna Got a Boost From Bird Flu, but Dont Count Your Chicks (The Wall Street Journal)
07:20AM	CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update (ACCESSWIRE)
May-15-24 01:54PM	CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
May-10-24 06:36AM	3 Stocks to Purge ASAP Before They're Pulled off Life Support (InvestorPlace)
Apr-25-24 01:30PM	CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.97%
05:10AM	Analyst Report: CureVac N.V. (Morningstar Research)
Apr-24-24 12:27PM	CureVac Begins Early Stage Portion of Investigational Vaccine Trial (MT Newswires)
07:30AM	CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update (ACCESSWIRE)
07:20AM	CureVac Appoints Thaminda Ramanayake as New Chief Business Officer (ACCESSWIRE)
07:20AM	CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK (ACCESSWIRE)
06:22AM	CureVac to cut costs in restructuring (BioPharma Dive)
Apr-18-24 07:15AM	CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 (ACCESSWIRE) -5.06%
Apr-16-24 07:15AM	CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines (ACCESSWIRE)
Apr-04-24 09:10AM	CureVac, chasing Moderna's mRNA flu vaccine, runs into the same B strain problems (FierceBiotech.com)
07:15AM	CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK (ACCESSWIRE)
Feb-22-24 06:55PM	Analyst Report: CureVac N.V. (Morningstar Research)
Jan-26-24 09:35AM	Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) (Zacks)
Jan-25-24 09:35AM	Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) (Zacks)
Jan-05-24 10:47AM	CureVac touts COVID-19 vax data as platform validation, despite grade 3 adverse events (FierceBiotech.com)
07:30AM	CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform (ACCESSWIRE)
Dec-30-23 08:49AM	13 Best Get Rich Quick Stocks To Buy (Insider Monkey)
Dec-19-23 10:15PM	Analyst Report: CureVac N.V. (Morningstar Research) -29.55%
01:43PM	Rebel's Edge - December 19: $RUN, $AFRM, $CVAC, and College Football Recruits (TheStreet.com)
12:31PM	Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today? (Benzinga)
09:35AM	CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE (ACCESSWIRE)
09:12AM	UPDATE 2-German court quashes CureVac patent after challenge by BioNTech (Reuters)
08:35AM	German court quashes CureVac patent after challenge by BioNTech (Reuters)
Nov-21-23 09:55AM	Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-20-23 03:41PM	Analyst Report: CureVac N.V. (Morningstar Research)
Nov-15-23 01:58PM	CureVac N.V. (NASDAQ:CVAC) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:03AM	Q3 2023 CureVac NV Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:30AM	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update (ACCESSWIRE)
Nov-01-23 08:15AM	CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK (ACCESSWIRE)
Oct-31-23 07:12PM	12 Best German Stocks To Buy Now (Insider Monkey)
Sep-29-23 09:07AM	Why CureVac Stock Plunged Today (Motley Fool) +5.08%
Sep-28-23 11:27AM	UPDATE 1-German court suspends mRNA patent trial against BioNTech (Reuters) -8.58%
07:15AM	CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany (ACCESSWIRE)
04:16AM	CORRECTED-German court suspends mRNA patent trial against BioNTech (Reuters)
Sep-27-23 06:44PM	Analyst Report: CureVac N.V. (Morningstar Research)
Sep-12-23 07:15AM	CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage (ACCESSWIRE)
Aug-17-23 07:15AM	CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update (ACCESSWIRE) -8.08%
Aug-08-23 06:26AM	Further weakness as CureVac (NASDAQ:CVAC) drops 9.7% this week, taking one-year losses to 40% (Simply Wall St.)
Aug-01-23 07:15AM	CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK (ACCESSWIRE)
Jul-20-23 06:01AM	The Petri Dish: CureVac's top scientist steps down; Novo Nordisk inks another Boston collab (American City Business Journals)
Jul-14-23 07:15AM	CureVac Announces Update to the Management Team (ACCESSWIRE)
Jul-13-23 07:15AM	CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights (ACCESSWIRE)
Jun-28-23 02:40PM	Are Investors Undervaluing CureVac N.V. (NASDAQ:CVAC) By 45%? (Simply Wall St.)
Jun-23-23 12:35PM	Why Shares of CureVac Jumped This Week (Motley Fool) +7.17%
Jun-20-23 06:29PM	Why CureVac Stock Leaped 12% Higher Today (Motley Fool) +12.01%
07:25AM	CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma (ACCESSWIRE)
07:10AM	CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board (ACCESSWIRE)
Jun-19-23 01:33PM	CureVac Announces Voting Results of General Meeting (ACCESSWIRE)
Jun-01-23 02:15PM	CureVac First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) -5.60%

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mulbe in 2000 and is headquartered in Tubingen, Germany.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pierre Kemula	affiliate	Sep 27 '24	Proposed Sale	3.08	55	169		Sep 27 12:48 PM
Pierre Kemula	affiliate	Sep 25 '24	Proposed Sale	3.10	34,000	105,400		Sep 25 02:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVAC

CureVac N.V

Upgrade your FINVIZ experience